A5067487467- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Urological Disorders and Treatments
- Urinary and Genital Oncology Studies
- Urinary Bladder and Prostate Research
- Pelvic floor disorders treatments
- Sexual function and dysfunction studies
- Cancer Research and Treatments
- Ethics in Clinical Research
- Urinary Tract Infections Management
- Anesthesia and Neurotoxicity Research
- Health Systems, Economic Evaluations, Quality of Life
- Male Reproductive Health Studies
- Statistical Methods in Clinical Trials
- Advanced Radiotherapy Techniques
- Colorectal Cancer Screening and Detection
- Economic and Financial Impacts of Cancer
- Organ Donation and Transplantation
- Infant Nutrition and Health
- Amino Acid Enzymes and Metabolism
- Kidney Stones and Urolithiasis Treatments
- Hemodynamic Monitoring and Therapy
- Central Venous Catheters and Hemodialysis
- Pancreatic and Hepatic Oncology Research
Freeman Hospital
1994-2023
University of Cambridge
2009
University of Bristol
2003
Newcastle University
2000
Newcastle upon Tyne Hospital
2000
Princess Royal Hospital
1986
Cheltenham General Hospital
1979
The comparative effectiveness of treatments for prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertain.
Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer was diagnosed 2664 men. Of these men, 1643 were enrolled trial to evaluate effectiveness treatments, with 545 randomly assigned receive active monitoring, 553 undergo prostatectomy, radiotherapy.
No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Feb 2000A PROSPECTIVE ANALYSIS OF 1,930 PATIENTS WITH HEMATURIA TO EVALUATE CURRENT DIAGNOSTIC PRACTICE M.H. Khadra, R.S. Pickard, M. Charlton, P.H. Powell, and D.E. Neal KhadraM.H. Khadra , PickardR.S. Pickard CharltonM. Charlton PowellP.H. Powell NealD.E. View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)67916-5AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints...
T he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced most efficient way for those who use, manage provide care NHS.Initially, six HTA panels (pharmaceuticals, acute sector, primary community care, diagnostics imaging, population screening, methodology) helped priorities Programme.However, during past few years there have been a number...
The ProtecT trial reported intention-to-treat analysis of men with localised prostate cancer (PCa) randomly allocated to active monitoring (AM), radical prostatectomy, and external beam radiotherapy. To determine report outcomes according treatment received in randomised choice cohorts. This study focuses on secondary care. Men clinically at one nine UK centres were invited participate the comparing AM, Two cohorts included 1643 who agreed be randomised; 997 declined randomisation chose...
Summary The results of a retrospective comparative study 122 patients who underwent explorations the common bile duct in district general hospital over 5-year period are presented. Seventy-eight had supraduodenal choledochotomy, 32 transduodenal sphincterotomy and 12 combination both procedures. Particular attention was paid to postoperative complications relation grade surgeon performing operation also age patient. A total 78 (64 per cent) definite stones duct. Of these patients, 7 (9 were...
To determine, within the UK, stage and grade of prostate cancers that would be found through population-based specific antigen (PSA) testing biopsy.In 'Prostate Testing for Cancer Treatment' trial (ProtecT), men aged 50-69 years were recruited from nine cities in UK randomly selected practices general practitioners. Those with a PSA level >3 ng/mL offered biopsy. Age, PSA, at diagnosis ProtecT participants cancer compared contemporaneous incident cases (age-restricted Registry cases)...
Background Prostate cancer is the most common among men in UK. Prostate-specific antigen testing followed by biopsy leads to overdetection, overtreatment as well undertreatment of disease. Evidence treatment effectiveness has lacked because paucity randomised controlled trials comparing conventional treatments. Objectives To evaluate treatments for localised prostate (active monitoring, radical prostatectomy and radiotherapy) aged 50–69 years. Design A prospective, multicentre...
Data concerning the relative efficacy of intravesical bacillus Calmette-Guerin (BCG) on subgroups carcinoma in situ bladder are limited. We report outcome primary and associated with Ta or T1 transitional cell treated BCG.Between 1987 1997, 135 patients (median age 70 years) biopsy proven underwent a standard course 6 BCG instillations. Patients were divided into group 1-23 situ, 2-37 3-75 carcinoma.Median followup was 41 months. For groups 1 to 3, complete response rates at 3 months 74% (17...
Summary— The clinical outcome of 278 prostate cancer patients managed by a deferred treatment policy was analysed retrospectively. Following TURP or biopsy, all were asymptomatic and deemed suitable for management policy, i.e. hormone therapy other forms only initiated if when symptomatic progression occurred. overall 5‐year survival rate 30%; 18% died from causes without needing their cancer; 11% alive untreated after 5 years' follow‐up; 17% further treatment. Poor tumour grade, anaemia,...
Early detection and treatment of asymptomatic men with advanced high-risk prostate cancer (PCa) may improve survival rates. To determine outcomes for diagnosed PCa following prostate-specific antigen (PSA) testing who were excluded from the ProtecT randomised trial. Mortality was compared 492 followed up a median 7.4 yr to contemporaneous cohort UK Anglia Cancer Network (ACN) matched subset ACN. PCa-specific all-cause mortality using Kaplan-Meier analysis Cox's proportional hazards...
To investigate the efficacy of epididymectomy in patients with significant scrotal pain after vasectomy.Sixteen were identified retrospectively to have undergone for vasectomy; 19 epididymectomies performed (three bilateral and 13 unilateral). Details from preoperative investigations, histological examination follow-up symptoms analysed correlated. Outcomes initially assessed at routine outpatient clinic review 3 months surgery long-term outcomes by a telephone interview 3-8 years (mean 5.5...
Summary— Two hundred and fifty‐three men (age 69.2pL7 years) undergoing prostatectomy for bladder outflow obstruction were studied. The aims to determine the distribution of voiding pressures their relationship presenting symptoms urodynamic findings. Symptoms scored by means a standardised questionnaire studies performed. Within this study group, high obstructive symptom scores associated with low flow rates urethral resistance. However, not statistically or symptoms. Voiding followed...
Summary— An assessment of the prototype Olympus Flexible Cystoscope in routine urological practice is presented. The results show that instrument compares favourably all respects with standard rigid equipment and has advantage cystoscopy can be performed supine under local anaesthesia ease. Biopsies may taken; small lesions fulgurised ureteric catheterisation without general anaesthesia.
SummaryThe introduction of urodynamic investigations has advanced our understanding the pathophysiology female lower urinary tract. The place studies in routine assessment patients with urological and gynaecological symptoms yet to be identified. purpose presented here was assess impact a service into busy clinical practice, regard both accuracy diagnosis and, as result, any subsequent changes results management.
The UK National Institute for Health and Clinical Excellence (NICE) guidance recommends conservative management of men with ‘low-risk’ localised prostate cancer, monitoring the disease using prostate-specific antigen (PSA) kinetics re-biopsy. However, there is little evidence changes in PSA level that should alert to need clinical re-assessment. This study compares alerts resulting from a novel longitudinal reference range approach, which incorporates age-related changes, during 408 cancer....